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ReiMbuRseMent Decisions in oncology DRugs: An inteRnAtionAl 
AnAlysis
Aissaoui A
Paris dauphine University, Paris, France
Objectives: The aim is to compare the drug reimbursement decisions of innova-
tive anti-cancer drugs in five countries (UK, France, Italy, Spain & Australia). Our 
approach was to identify both convergence and divergence in these reimbursement 
decisions and to assess the agreement level between the policy makers. MethOds: 
For our analysis we have used 39 oncology drugs authorized by the EMA between 
January 2004 and December 2012 covering a total of 65 indications, and we have 
compared the reimbursement decisions in theses 5 countries. We reviewed the 
technology appraisal performed by their respective national HTA agencies and their 
reimbursement decisions. We have also analyzed the level of agreement for reim-
bursement decisions between pairs of each country with kappa scores. Results: 
Out of these 39 drugs, only 16 drugs were reimbursed in Australia, 15 in England, 
38 in France, followed by Italy and Spain, which respectively reimbursed 29 and 28 
drugs. When we have analyzed the common reimbursement decision taken, we 
have observed that between France and Italy 72% of common positive reimburse-
ment decision were taken, and between France and England only 33 % of positive 
reimbursement decisions are common. In contrast we have found 49 % of common 
negative reimbursement decision between England and Australia. Then we have 
measured the consistency between decision makers with KAPPA scores and it came 
out that France, Italy and Spain are often in agreement in their reimbursement deci-
sions, and that conversely France and England decisions are significantly in disa-
greement. cOnclusiOns: This study demonstrates that the discordance between 
countries reimbursement decisions, in most cases may reflect the differences in 
the decision making process (Eg. France Vs England). But this analysis cannot be 
conclusive. This is why we have carried out further researches using larger datasets 
allowing us to highlight some elements yielding to these reimbursement decision 
differences between countries.
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eAsy coMe, HARDly go: ePiDeMiologicAl MetHoDs to evAluAte tHe 
effect of isPoR boARD of DiRectoRs MeMbeRsHiP on PublicAtion 
Activity
Merész G.1, Gyurcsán G.C.2, Salfer B.3
1Syreon Research Institute, Budapest, Hungary, 2Self-employed, Budapest, Hungary, 3Healthware 
Consulting Ltd., Budapest, Hungary
Objectives: ISPOR is approaching its 10th anniversary, which offers a suitable occa-
sion to assess the impact of the organization. As the number of members increased, 
the influence of the Board of Directors on scientific discussions also emerged. The 
aim of this research is to present what effect being elected an ISPOR Director has 
on a researcher’s publication activity by using epidemiological methods and data 
mining techniques. MethOds: Data on number of publications by year, co-authors, 
titles, abstracts of former ISPOR Directors between 1995 and 2012 were obtained 
from public sources (ISPOR website and PubMed) and analysed by an algorithm 
developed by the authors in R. A case-only study design was applied by matching the 
duration spent as a member of the Board of Directors with the same period prior to 
and after finishing the directorate term. Incidence rate ratios (IRR) were estimated 
by fitting separate Poisson regression models to correct for the baseline increase 
in publication activity. The average number of co-authors and probability of the 
director being the first author was also analysed. Results: The IRR of the period 
preceding to directorate versus the directorate period was 1.59 (CI 95%: 1.34-1.91), 
yielding statistically significant association. The IRR of directorate period versus the 
period succeeding the directorate period was 1.01 (CI 95%: 0.88-1.13). The average 
number of co-authors was the highest after the directorate term (5.94); the probabil-
ity of the director appearing as the first author was the highest prior to directorate 
term (22.91%). cOnclusiOns: As a result of our study, it has been statistically 
proven that being an ISPOR Director does not only provide leadership in a scientific 
organization, but can enhance the members’ career as a researcher. ISPOR Directors 
are more likely to co-author publications even after finishing their directorate term.
ReseARcH on MetHoDs – Modeling Methods
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cReAting PAtient PRofile in inDiviDuAl siMulAtions: A coMPARison of 
APPRoAcHes
Stern S., Pan F
Evidera, Bethesda, MD, USA
Objectives: Individual simulation is increasingly used in economic models, partly 
because of its capability of predicting event risks based on individual patient char-
acteristics. However, due to lack of individual patient level data, models often use 
means and standard deviations to create patient profiles. The objective of this study 
is to evaluate different simulation approaches of creating patient profile at baseline 
and their impact on model outcomes. MethOds: Patient level data (N= 8,857) from 
National Health and Nutrition Examination Survey (NHANES) was used to evalu-
ate three approaches of creating baseline patient profiles for simulation models. 
10 samples of 1000 patients each were created through 1) random sampling from 
patient level data; 2) using means and standard deviations of the profile variables 
without correlating the characteristics; 3) using means and variance-covariance 
matrix among the continuous variable characteristics with cholesky decomposi-
tion approach. 10-year cardiovascular diseases (CVDs) rates are estimated using the 
created patient profiles from these 3 different approaches. Results: The predicted 
CVD rates based on random sampling are 18.2% for males and 9.7% for females using 
the random sampling approach, 14.5% for males and 7.9% for females using the 
mean and standard deviation approach and 16.0% for males and 9.2% for females 
using the cholesky decomposition approach. The CVD rates using the NHANES entire 
positive association (p< 0.05) with different cardiovascular outcomes. However, in 
the multivariate models, only those experiencing heartburn (adjusted OR 1.3, 95% 
CI 1.0-1.7) during pregnancy were at greater risk of having hypertension 21 years 
post partum. Women experiencing morning sickness (adjusted OR 1.2, 95% CI 0.8-
2.0) and backache (adjusted OR 1.1, 95% CI 0.6-1.7) were not considered to be at 
risk for future heart disease. cOnclusiOns: As a whole, our study suggests that 
most common symptoms of pregnancy are not associated with an increased risk 
of cardiovascular disease or with hypertension in the long term.
PRM68
incReAseD AccuRAcy of DistRibution bAseD Missing vAlue iMPutAtion: 
An AlteRnAtive to MeAn inPutAtion in ReAl WoRlD enviRonMent 
suRvey ReseARcH
Wasser T., Eisenberg D.
HealthCore, Inc., Wilmington, DE, USA
Objectives: Missing values within variables can impede accurate data analysis 
on many levels including both univariate and multivariate analysis. This research 
presents distribution-based imputation (DBI), where the distribution of non-missing 
values is simulated to create a set of values that are then randomly inserted into to 
the missing values in the actual data and compares this against mean based imputa-
tion (MBI). MethOds: DBI was compared to MBI in 12 different simulation condi-
tions based on three sample sizes (50, 100, 150 and 200) and three different missing 
value percentages for each of the sample sizes (10%, 20% and 30%). Each simulation 
created 1,000 test datasets within each condition for a total of 12,000 simulated 
datasets. The statistical package, R was used for the sumilation. Results: MBI 
was biased by simulating smaller Standard Deviations, and less accurate in mean 
estimation than DBI in all 12 simulation combinations. DBI was more accurate in 
matching the number of rejected hypotheses as compared to the gold standard. 
Comparing the calculated p-values for bias where an unbiased estimator would 
demonstrate a 50/50 split being greater than and less than the gold standard, DBI 
was closer to the gold standard with at 48.7/51.3 split, as compared to the 25.8/74.2 
split of MBI. cOnclusiOns: DBI was found to be more accurate and unbiased as 
compared to MBI methods. As a result, when studies are small and do not contain a 
large number of variables, or in situations where more elaborate imputation meth-
ods cannot be done, DBI is an accurate and unbiased method.
PRM69
inDiRect coMPARison of tHe effects of Anti-tnf biologicAl Agents 
in PAtients WitH AnKylosing sPonDylitis by MeAns of A MiXeD 
tReAtMent coMPARison PeRfoRMeD on efficAcy DAtA fRoM PublisHeD 
RAnDoMiseD, contRolleD tRiAls
Migliore A., Bizzi E., Massafra U.
S. Pietro Fatebenefratelli Hospital, Rome, Italy
Objectives: To compare ASAS (Assessment in Ankylosing Spondylitis Response 
Criteria) 20 response patterns between anti-TNF biological agents in patients with 
ankylosing spondylitis by means of a mixed treatment comparison of different ran-
domised, controlled trials (RCTs) on the efficacy of biological therapies. MethOds: 
A systematic review of literature was performed to identify a number of similarly 
designed double-blind, randomized, placebo-controlled trials investigating the effi-
cacy of the TNF-alfa inhibitors etanercept, infliximab, golimumab, certolizumab 
pegol and adalimumab in the treatment of ankylosing spondylitis patients, con-
ducted over an 18-years period. The endpoint of interest was ASAS20 response 
criteria at 12 weeks. Results were analyzed simultaneously using Bayesian mixed 
treatment comparison techniques. Results were expressed as odds ratio (OR) of 
ASAS20 response and associated 95% credible intervals (CrIs). The probability of 
being the best treatment was also reported. Results: 6 RCTs were selected for data 
extraction and further analysis. By mean of MTC, all anti-TNF agents demonstrated 
to be more efficacious in inducing a ASAS20 response than placebo. Infliximab 
shows a 67,6% of probability of being the best treatment of all. Adalimumab, goli-
mumab and etanercept show probabilities of 17,7%, 10,6% and 4%, respectively, 
while certolizumab pegol showed a probability of being the best treatment of 0,1%. 
No differences were observed when comparing directly an anti-TNFalfa agent 
against another. cOnclusiOns: Even if the mixed treatment comparisons between 
infliximab, golimumab, certolizumab pegol, adalimumab and etanercept did not 
show a statistically signiﬁcant difference, this analysis suggests that infliximab, 
compared to placebo, is expected to provide the highest rate of ASAS20 response 
in SA patients naive to biologic treatments.
PRM70
A tutoRiAl on DiMensionAlity ReDuction in lARge clAiMs DAtA sets
Juneau P.
Truven Health Analytics, Boyds, MD, USA
Objectives: The objective of this presentation will be to introduce the audience 
to various data dimension reduction techniques that may be applied in the setting 
of a large commercial claims data set to facilitate the task of identifying important 
factors or key features for use in subsequent analysis. MethOds: The author will 
provide a brief survey of the data dimension reduction literature from areas as 
diverse as image analysis, neural networks, gene expression microarrays, and high 
through-put chemistry to demonstrate that despite that many of these techniques 
have been used in other settings or areas of research, their application to the analy-
sis of health care claims data is relevant and potentially quite useful. Results: 
One, all-purpose, optimal data dimension technique does not exist for application 
in the analysis of health care claims data. The analyst needs to weigh the features 
of the large data set under consideration, the objectives of the downstream or sub-
sequent analysis, and the availability of tools for ease of use and interpretation 
of results. cOnclusiOns: The number of data dimension reduction techniques 
available to claims data set researchers is large and diverse; however, keys features 
of these various approaches can help the analyst make an informed decision that 
is effective with some simple setting and objectives diagnosis.
